[Converting enzyme inhibitors and cardiac insufficiency: current findings and perspectives].
Angiotensin-converting enzyme inhibitors are mixed vasodilators with a prolonged sustained effect in chronic heart failure. They also act on the reactivity of peripheral circulation, on ventricular remodelling after myocardial infarction, on myocardial hypertrophy in arterial hypertension and on ventricular hyperexcitability. They alleviate the symptoms of symptomatic heart failure, and they constitute the only treatment that has been able to improve the survival of patients with the most severe heart failure. Several studies are in progress to determine whether these drugs should be used as first-line therapy.
Cohen-Solal
A
A
Service de cardiologie, hôpital Bichat, Paris.
Laperche
T
T
Makowski
S
S
Aumont
M C
MC
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D012039:Regional Blood Flow / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors
Inhibiteurs de l'enzyme de conversion et insuffisance cardiaque: données actuelles et perspectives.